Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

63.32USD
20 Jul 2018
Change (% chg)

$-0.46 (-0.72%)
Prev Close
$63.78
Open
$63.61
Day's High
$64.04
Day's Low
$63.28
Volume
5,813,660
Avg. Vol
5,620,515
52-wk High
$65.50
52-wk Low
$48.05

Latest Key Developments (Source: Significant Developments)

Clearstar Says Clearmd Mobile Drug Testing Solution Integrated With Abbott
Wednesday, 20 Jun 2018 02:00am EDT 

June 20 (Reuters) - CLEARSTAR INC ::CLEARMD MOBILE DRUG TESTING SOLUTION IS NOW INTEGRATED WITH ABBOTT LABORATORIES.  Full Article

Abbott Says Newest Generation Of Leading Heart Stent Now Approved In U.S. For People With Coronary Artery Disease
Wednesday, 23 May 2018 09:00am EDT 

May 23 (Reuters) - Abbott Laboratories ::ABBOTT - NEWEST GENERATION OF LEADING HEART STENT NOW APPROVED IN U.S. FOR PEOPLE WITH CORONARY ARTERY DISEASE.  Full Article

Abbott's Investigational Tendyne Device For Mitral Valve Replacement Demonstrates Positive Outcomes At 30 Days In Global Study
Wednesday, 23 May 2018 06:00am EDT 

May 23 (Reuters) - Abbott Laboratories ::ABBOTT'S INVESTIGATIONAL TENDYNE™ DEVICE FOR MITRAL VALVE REPLACEMENT DEMONSTRATES POSITIVE OUTCOMES AT 30 DAYS IN GLOBAL STUDY.DEVICE WILL BE FURTHER STUDIED IN U.S. PIVOTAL STUDY.  Full Article

5-Year Study Data Confirm Positive Outcomes For Patients When Abbott Diagnostic Tool Was Used To Guide Heart Stenting Decisions
Tuesday, 22 May 2018 06:20am EDT 

May 22 (Reuters) - Abbott Laboratories ::FIVE-YEAR STUDY DATA CONFIRM POSITIVE OUTCOMES FOR PATIENTS WHEN ABBOTT DIAGNOSTIC TOOL WAS USED TO GUIDE HEART STENTING DECISIONS.  Full Article

Abbott's MitraClip Therapy Receives National Reimbursement In Japan To Treat Patients With Mitral Regurgitation
Monday, 19 Mar 2018 09:00am EDT 

March 19 (Reuters) - Abbott Laboratories ::ABBOTT'S MITRACLIP THERAPY RECEIVES NATIONAL REIMBURSEMENT IN JAPAN TO TREAT PATIENTS WITH MITRAL REGURGITATION.ABBOTT LABORATORIES - ‍MITRACLIP SYSTEM IS APPROVED IN JAPAN FOR TREATMENT OF BOTH SEVERE DEGENERATIVE MITRAL REGURGITATION AND FMR HEART DISEASES​.ABBOTT-MINISTRY OF HEALTH LABOUR AND WELFARE IN JAPAN GRANTED NATIONAL REIMBURSEMENT FOR CO'S MITRACLIP THERAPY TO TREAT MITRAL REGURGITATION.  Full Article

FDA Approves The World's Smallest Mechanical Heart Valve
Tuesday, 6 Mar 2018 06:07pm EST 

March 6 (Reuters) - Abbott Laboratories ::FDA APPROVES THE WORLD'S SMALLEST MECHANICAL HEART VALVE FOR PEDIATRIC PATIENTS WITH HEART DEFECTS.  Full Article

U.S. FDA Expands Approval Of A Heart Valve To Include Size For Newborn Children
Tuesday, 6 Mar 2018 01:55pm EST 

March 6 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS EXPANDED APPROVAL OF A HEART VALVE TO INCLUDE A SIZE SMALL ENOUGH TO BE USED IN NEWBORN PEDIATRIC PATIENTS TO TREAT HEART DEFECTS.U.S. FDA SAYS GRANTED APPROVAL OF MASTER SERIES HEART VALVE TO ST JUDE MEDICAL.U.S. FDA SAYS APPROVED THE MASTERS SERIES MECHANICAL HEART VALVE WITH HEMODYNAMIC PLUS SEWING CUFF TO INCLUDE THE 15-MM VALVE SIZE.  Full Article

Abbott And Surmodics Announce Agreement For Next-Generation Drug-Coated Balloon
Tuesday, 27 Feb 2018 09:00am EST 

Feb 27 (Reuters) - Abbott Laboratories ::ABBOTT AND SURMODICS ANNOUNCE AGREEMENT FOR NEXT-GENERATION DRUG-COATED BALLOON.SURMODICS INC - ‍PURSUANT TO TERMS OF AGREEMENT, SURMODICS WILL RECEIVE A $25 MILLION UPFRONT PAYMENT​.SURMODICS INC - ‍PURSUANT TO TERMS OF AGREEMENT, CO MAY EARN AN ADDITIONAL $67 MILLION FOR VARIOUS PRODUCT DEVELOPMENT MILESTONES​.SURMODICS - ENTERED INTO AGREEMENT WHEREBY ABBOTT WILL HAVE EXCLUSIVE WORLDWIDE COMMERCIALIZATION RIGHTS FOR CO'S SURVEI DRUG-COATED BALLOON.SURMODICS INC - WILL BE RESPONSIBLE FOR MANUFACTURE AND SUPPLY OF CLINICAL AND COMMERCIAL QUANTITIES OF PRODUCT​.SURMODICS INC - ‍ABBOTT ALSO RECEIVED OPTIONS TO NEGOTIATE AGREEMENTS FOR CO'S BELOW-THE-KNEE AND AV FISTULA DRUG-COATED BALLOON PRODUCTS​.  Full Article

Abbott Sets Quarterly Dividend Of $0.28/Share
Friday, 16 Feb 2018 11:20am EST 

Feb 16 (Reuters) - Abbott ::ABBOTT SETS QUARTERLY DIVIDEND OF $0.28PER SHARE.  Full Article

Agios says FDA Accepts NDA And Grants Priority Review For Ivosidenib
Thursday, 15 Feb 2018 11:58am EST 

Feb 15 (Reuters) - Agios Pharmaceuticals Inc ::FDA ACCEPTS NEW DRUG APPLICATION AND GRANTS PRIORITY REVIEW FOR IVOSIDENIB IN RELAPSED OR REFRACTORY AML WITH AN IDH1 MUTATION.FDA ACCEPTS NEW DRUG APPLICATION AND GRANTS PRIORITY REVIEW FOR IVOSIDENIB IN RELAPSED OR REFRACTORY AML WITH AN IDH1 MUTATION.AGIOS PHARMACEUTICALS INC - ‍PDUFA DATE SET FOR AUGUST 21, 2018​.AGIOS PHARMACEUTICALS - ABBOTT SUBMITTED PREMARKET APPROVAL APPLICATION FOR FDA REVIEW OF AN IDH1 ASSAY ON ABBOTT M2000 REALTIME SYSTEM​.AGIOS PHARMACEUTICALS INC - ‍ABBOTT ASSAY WILL SERVE AS A COMPANION DIAGNOSTIC FOR IVOSIDENIB​.  Full Article

Photo

Abbott Labs raises 2018 earnings forecast, shares hit record high

Abbott Laboratories raised its full-year earnings forecast and topped estimates for quarterly profit on Wednesday, powered by demand for its glucose monitoring device for diabetics and gains from its multibillion dollar acquisitions.